Attitudes of Korean clinicians to postmenopausal hormone therapy after the Women's Health Initiative study

Menopause

Volumn 13, Issue 1, 2006, Pages 125-129

  Kang, Byung M ^a   Kim, Mee Ran ^b   Park, Hyoung M ^c   Yoon, Byung K ^d   Lee, Byung S ^e   Chung, Hye W ^f   Cho, Soo H ^g   Choi, Hoon ^h   Kim, Jung G ⁱ  

^a University of Ulsan College of Medicine   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Chung Ang University College of Medicine   (South Korea)

^d Sungkyunkwan University   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

^f Ewha Womans University School of Medicine   (South Korea)

^g Hanyang University   (South Korea)

^h Inje University   (South Korea)

ⁱ Seoul National University   (South Korea)

Author keywords

Hormone therapy; Questionnaire; Women's Health Initiative study

Indexed keywords

CONJUGATED ESTROGEN; CYPROTERONE ACETATE; ESTRADIOL; ESTRADIOL VALERATE; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; TIBOLONE; PREGNANE DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; FEMALE; HORMONAL THERAPY; HUMAN; KOREA; MAJOR CLINICAL STUDY; OSTEOPOROSIS; PRESCRIPTION; PUBLICATION; QUESTIONNAIRE; TREATMENT REFUSAL; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; ESTROGEN THERAPY; HEALTH PERSONNEL ATTITUDE; MALE; METHODOLOGY; MIDDLE AGED; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; STATISTICS; WOMEN'S HEALTH;

ADULT; ATTITUDE OF HEALTH PERSONNEL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; KOREA; MALE; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; NORPREGNENES; OSTEOPOROSIS, POSTMENOPAUSAL; PHYSICIAN'S PRACTICE PATTERNS; POSTMENOPAUSE; PRESCRIPTIONS, DRUG; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS; WOMEN'S HEALTH;

EID: 33645974867     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gme.0000191211.51232.9d     Document Type: Article

References (9)

1. Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
2. The Study Group for Menopause. Trends and attitudes to postmenopausal hormone replacement therapy in Korea. J Korean Soc Menopause 2003;9:51-57.
3. The Study Group for Menopause. Trends and attitudes toward prescribing hormone replacement therapy during menopause in Korea. J Korean Soc Menopause 2003;9:177-182.
4. The Study Group for Menopause. Trends and attitudes of Korean physicians toward recommending when hormone replacement therapy is started and how long it is continued. J Korean Soc Menopause 2003;9:273-279.
5. The Study Group for Menopause. Trends and attitudes toward postmenopausal osteoporosis in Korea. J Korean Soc Menopause 2003;9:353-359.
6. The North American Menopause Society. Role of progestogen in hormone therapy for postmenopausal women: position statement of The North American Menopause Society. Menopause 2003;10:113-132.
7. Lam PM, Cheung GWY, Shek DTL, Lee DTS, Haines CJ, Chung TKH. A randomized, placebo controlled, crossover study of tibolone (Livial) on menopause symptoms, psychological well-being, and dyadic relationship of postmenopausal Chinese women and their spouses. Menopause 2004;11:416-422.
8. 2/NETA on the reduction of postmenopausal bone loss in women. Menopause 2003;10:241-249.
9. Gompel A, Siromachkova M, Lombet A, Kloosterboer HJ, Rostene W. Tibolone actions on normal and breast cancer cells. Eur J Cancer 2000;36(Suppl 4):76S-77S.